Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Ryan C Fields

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6176-8943; OpenAlex author ID A5081302342; NIH RePORTER profile ID 8182718. Sources: ClinicalTrials.gov.

Their work

Papers
35 (first author 2, last author 3)
Trials
1 (principal investigator on 1)
Grants
6
Labs led
1
Collaborators
123
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper, 1 trial · 2014: 2 papers · 2015: 1 paper, 1 grant · 2016: 1 paper · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers · 2020: 3 papers, 1 grant · 2021: 2 papers · 2022: 1 paper · 2023: 7 papers, 1 grant · 2024: 5 papers, 1 grant · 2025: 3 papers · 2026: 1 paper, 2 grants

Papers 35

  1. Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.017↗
  2. Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade Co-author DOI 10.1101/2025.10.08.681226↗
  3. Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancer. Co-author DOI 10.1126/sciimmunol.adp3978↗
  4. HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-2200↗
  5. Female-specific pancreatic cancer survival from CT imaging of visceral fat implicates glutathione metabolism in solid tumors. Co-author DOI 10.1016/j.acra.2023.11.012↗
  6. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗
  7. Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1080/2162402x.2024.2320411↗
  8. Senescence Defines a Distinct Subset of Myofibroblasts That Orchestrates Immunosuppression in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-23-0428↗
  9. Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-16245-1↗
  10. Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC). Last author DOI 10.1016/j.hpb.2023.08.005↗
  11. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial. Co-author DOI 10.1016/j.ijrobp.2022.07.015↗
  12. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Co-author DOI 10.1038/s41590-023-01579-x↗
  13. High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival. Co-author DOI 10.1038/s41698-023-00455-z↗
  14. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. Co-author DOI 10.1084/jem.20212062↗
  15. Single-cell transcriptomics reveals long noncoding RNAs associated with tumor biology and the microenvironment in pancreatic cancer. Co-author DOI 10.1093/narcan/zcad055↗
  16. Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-21-0946↗
  17. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Co-author DOI 10.1038/s41588-022-01157-1↗
  18. Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Co-author DOI 10.1016/j.adro.2020.06.010↗
  19. Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-0998↗
  20. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.02.008↗
  21. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Co-author DOI 10.1136/gutjnl-2018-317424↗
  22. B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-19-0349↗
  23. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  24. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Co-author DOI 10.1126/scitranslmed.aau9240↗
  25. Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.031↗
  26. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Co-author DOI 10.1038/s41467-018-03600-6↗
  27. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic du… Co-author DOI 10.1136/gutjnl-2017-313738↗
  28. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. Co-author DOI 10.1016/j.hpb.2017.01.012↗
  29. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Co-author DOI 10.1016/j.immuni.2017.07.014↗
  30. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/s1470-2045(16)00078-4↗
  31. Natural history of preoperative subcentimeter pulmonary nodules in patients with resectable pancreatic adenocarcinoma: a retrospective cohort study. Last author DOI 10.1097/sla.0000000000000719↗
  32. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  33. Inflammatory, insulin resistance metabolic markers and pancreatic cancer: quo vadis? [corrected]. First author DOI 10.2217/fon.14.88↗
  34. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4236/jct.2013.43096↗
  35. Left-sided pancreatic cancer: distal pancreatectomy and its variants: radical antegrade modular pancreatosplenectomy and distal pancreatectomy with celiac axis… First author DOI 10.1097/ppo.0b013e31827596c5↗

Trials 1

  1. Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma Principal investigator NCT02028377↗

Grants 6

  1. Core A: Administrative Core P50CA272213↗
  2. The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity U01CA284086↗
  3. Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model R01CA248277↗
  4. Data Processing, Analysis and Modeling Unit U2CCA233303↗
  5. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗
  6. EVALUATION OF POSITRON EMISSION TOMOGRAPHY-MAGNETIC RESONANCE IMAGING (PET-MRI) R21CA179541↗

Closest collaborators

The 25 strongest of 123 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David G DeNardo · 21 shared papers, 3 shared grants, 2013–2026 · strength 4.73
  2. William G. Hawkins · 25 shared papers, 2 shared grants, 2013–2026 · strength 3.74
  3. Li Ding · 5 shared papers, 2 shared grants, 2023–2026 · strength 2.31
  4. Kian‐Huat Lim · 8 shared papers, 1 shared grant, 2016–2026 · strength 1.98
  5. William E. Gillanders · 2 shared papers, 3 shared grants, 2018–2026 · strength 1.74
  6. Graham D. Hogg · 7 shared papers, 2019–2025 · strength 0.95
  7. Richard A Flavell · 1 shared grant, 2024 · strength 0.91
  8. Andrea Wang‐Gillam · 7 shared papers, 1 shared grant, 2013–2024 · strength 0.85
  9. Liang‐I Kang · 5 shared papers, 2023–2025 · strength 0.84
  10. John M. Baer · 6 shared papers, 2018–2024 · strength 0.76
  11. Varintra E. Lander · 5 shared papers, 2020–2025 · strength 0.74
  12. Vikas Somani · 3 shared papers, 2024–2026 · strength 0.66
  13. Sapana Bansod · 3 shared papers, 2024–2026 · strength 0.66
  14. Chong Zuo · 6 shared papers, 2017–2023 · strength 0.62
  15. C. Alston James · 4 shared papers, 2021–2024 · strength 0.60
  16. Hyun Jee Kim · 4 shared papers, 2021–2024 · strength 0.55
  17. Samuel Achilefu · 1 shared grant, 2023 · strength 0.53
  18. Roheena Z. Panni · 6 shared papers, 2013–2025 · strength 0.48
  19. Ashenafi Shiferaw Bulle · 2 shared papers, 2024–2026 · strength 0.41
  20. Vikram S. Pothuri · 2 shared papers, 2023–2024 · strength 0.40
  21. Linda R. Peterson · 2 shared papers, 2024 · strength 0.37
  22. Joseph E. Ippolito · 2 shared papers, 2024 · strength 0.37
  23. Timothy M. Nywening · 4 shared papers, 2016–2024 · strength 0.37
  24. Blake E. Sells · 2 shared papers, 2024–2025 · strength 0.36
  25. Dominic E. Sanford · 4 shared papers, 2013–2023 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.